BACKGROUNDCommercial Manufacturing Agreement • April 4th, 2008 • Xanodyne Pharmaceuticals Inc • Pharmaceutical preparations • New York
COMMERCIAL MANUFACTURING AGREEMENT Salix Pharmaceuticals, Inc., Mesalamine Controlled Release CapsulesCommercial Manufacturing Agreement • August 17th, 2009 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • Delaware
This Commercial Manufacturing Agreement (“Agreement”) is made effective as of this 9th day of September, 2008 (“Effective Date”), by and between Salix Pharmaceuticals, Inc., a California corporation, with a place of business at 1700 Perimeter Park Drive, Morrisville, NC, 27560 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”).
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • August 8th, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS MANUFACTURING AGREEMENT (the “Agreement”) is made and entered into this 7th day of April, 2014 (the “Effective Date”), by and between AAIPharma Services Corp., having a place of business at 2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”) and Corcept Therapeutics Incorporated, having a place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Company”). AAIPharma and Company, as used herein, may be referred to, collectively, as “Parties” and individually as a “Party”.
COMMERCIAL MANUFACTURING AGREEMENT 1Commercial Manufacturing Agreement • May 6th, 2015 • Siga Technologies Inc • Pharmaceutical preparations
THIS 2015 AMENDMENT TO COMMERCIAL MANUFACTURING AGREEMENT (the “2015 Amendment”), dated as of __ __________ 2015, is by and among SIGA Technologies, Inc., a Delaware corporation, having a place of business at 660 Madison Avenue, Suite 1700, New York, NY, 10065 (“Customer”), and Albemarle Corporation, a Virginia corporation, with a place of business at 451 Florida Street, Baton Rouge, LA, 70801 (“Albemarle”).
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • October 22nd, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS MANUFACTURING AGREEMENT (the “Agreement”) is made and entered into this 7th day of April, 2014 (the “Effective Date”), by and between AAIPharma Services Corp., having a place of business at 2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”) and Corcept Therapeutics Incorporated, having a place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Company”). AAIPharma and Company, as used herein, may be referred to, collectively, as “Parties” and individually as a “Party”.
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • March 16th, 2006 • Collagenex Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
This Commercial Manufacturing Agreement (“Agreement”) is made this 30th day of December, 2005, by and between Cardinal Health PTS, LLC, having a place of business at 14 Schoolhouse Road, Somerset, NJ 08873 (“Cardinal Health”) and CollaGenex Pharmaceuticals, Inc. (“Client”), having its principal place of business at 41 University Drive, Suite 200, Newtown, PA 18940.
COMMERCIAL MANUFACTURING AGREEMENT (AVACOPAN)Commercial Manufacturing Agreement • November 9th, 2020 • ChemoCentryx, Inc. • Pharmaceutical preparations
THIS AGREEMENT (“Agreement”) is made and entered into as of August 17, 2020 (the “Effective Date”) by and between ChemoCentryx, Inc. a Delaware corporation, with offices at 850 Maude Avenue, Mountain View, CA 94043 (“Customer”), and Hovione LLC, with a mailing address at 40 Lake Drive, East Windsor, New Jersey 08520 (“Hovione”).
Addendum #3 to Commercial Manufacturing AgreementCommercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations
This Addendum to Commercial Manufacturing Agreement, (this “Addendum”) is entered into and effective the 2nd day of July, 2014 by and between Albemarle Corporation, (hereinafter “Albemarle”); and SIGA Technologies, Inc. (hereinafter “Customer”), to addend, amend and/or supplement that certain Commercial Manufacturing Agreement between Albemarle and customer dated August 25, 2011, as amended December 21, 2012 and July 1, 2013 (the “Commercial Manufacturing Agreement”). All capitalized terms used herein and not defined shall have the meaning set forth in the Commercial Manufacturing Agreement.
Addendum to Commercial Manufacturing AgreementCommercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations
This Addendum to Commercial Manufacturing Agreement, (this “Addendum”) is entered into and effective this ____ day of _____________, 2012, by and between Albemarle Corporation, (hereinafter “Albemarle”); and SIGA Technologies, Inc. (hereinafter “Customer”), to addend, amend and/or supplement that certain Commercial Manufacturing Agreement between Albemarle and Customer dated August 25, 2011 (the “Commercial Manufacturing Agreement”). All capitalized terms used herein and not defined shall have the meaning set forth in the Commercial Manufacturing Agreement.
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations • Delaware
This COMMERCIAL MANUFACTURING AGREEMENT (this “Agreement”) is entered into effective as of __________, 2011 (the “Effective Date”), by and between SIGA Technologies, Inc., a Delaware corporation (“Customer”), having a place of business at 35 E. 62nd Street, New York, NY, 10065, and Albemarle Corporation, a Virginia corporation (“Albemarle”), having a place of business at 451 Florida Street, Baton Rouge, Louisiana 70801. Each of Customer and Albemarle is sometimes referred to herein as a “Party” and collectively as the “Parties”.
COMMERCIAL MANUFACTURING AGREEMENT BETWEEN BLONDER TONGUE LABORATORIES, INC. AND HUGHES NETWORK SYSTEMS, A HUGHES ELECTRONICS CORPORATION FOR DIGITAL SATELLITE SYSTEM EQUIPMENTCommercial Manufacturing Agreement • May 14th, 1998 • Blonder Tongue Laboratories Inc • Radio & tv broadcasting & communications equipment • Delaware
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • March 6th, 2019 • Siga Technologies Inc • Pharmaceutical preparations • Delaware
This COMMERCIAL MANUFACTURING AGREEMENT (this “Agreement”) is entered into effective as of October 1, 2018 (the “Effective Date”), by and between SIGA Technologies, Inc., a Delaware corporation (“Customer”), having a place of business at 31 East 62nd Street, New York, NY, 10065, and Albemarle Corporation, a Virginia corporation (“Albemarle”), having a place of business at 4350 Congress Street, Suite 700, Charlotte, North Carolina 28209. Each of Customer and Albemarle is sometimes referred to herein as a “Party” and collectively as the “Parties”.
AMENDMENT ONE TO COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • November 19th, 2013 • Pharmacyclics Inc • Pharmaceutical preparations
ContractCommercial Manufacturing Agreement • November 9th, 2012 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
NOTE: CERTAIN CONFIDENTIAL INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT AND REPLACED BY "[*]". A COMPLETE COPY OF THIS DOCUMENT INCLUDING THE CONFIDENTIAL INFORMATION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • August 9th, 2017 • PTC Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS MANUFACTURING AGREEMENT (the “Agreement”) is made and entered into this 18th day of September, 2015 (the “Effective Date”), by and between AAIPharma Services Corp., having a place of business at 2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”) and Marathon Pharmaceuticals, LLC having a place of business at 1033 Skokie Blvd., Suite 600, Northbrook, IL 60062 USA (“Company”). AAIPharma and Company, as used herein, may be referred to, collectively, as “Parties” and individually as a “Party”.
AMENDMENT ONE TO COMMERCIAL MANUFACTURING AGREEMENTCommercial Manufacturing Agreement • August 14th, 2014 • Pharmacyclics Inc • Pharmaceutical preparations
